Navidea Biopharmaceuticals Inc EBITDA margin
What is the EBITDA margin of Navidea Biopharmaceuticals Inc?
The EBITDA margin of Navidea Biopharmaceuticals Inc is -20,121.97%
What is the definition of EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin of companies in the Health Care sector on NYSEMKT compared to Navidea Biopharmaceuticals Inc
What does Navidea Biopharmaceuticals Inc do?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Companies with ebitda margin similar to Navidea Biopharmaceuticals Inc
- Liminal BioSciences has EBITDA margin of -21,060.77%
- Peregrine Gold Ltd has EBITDA margin of -20,852.75%
- Deep Yellow has EBITDA margin of -20,849.54%
- Carnaby Resources has EBITDA margin of -20,627.90%
- Aurumin has EBITDA margin of -20,483.30%
- Nikola has EBITDA margin of -20,335.82%
- Navidea Biopharmaceuticals Inc has EBITDA margin of -20,121.97%
- Ookami has EBITDA margin of -20,061.27%
- Avita Medical has EBITDA margin of -20,041.38%
- Chant West has EBITDA margin of -19,997.24%
- Kingsland Global has EBITDA margin of -19,982.54%
- Crinetics Pharmaceuticals Inc has EBITDA margin of -19,941.16%
- E2 Metals has EBITDA margin of -19,921.03%